<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomol Struct Dyn</journal-id><journal-id journal-id-type="iso-abbrev">J. Biomol. Struct. Dyn</journal-id><journal-title-group><journal-title>Journal of Biomolecular Structure &#x00026; Dynamics</journal-title></journal-title-group><issn pub-type="ppub">0739-1102</issn><issn pub-type="epub">1538-0254</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7441776</article-id><article-id pub-id-type="doi">10.1080/07391102.2020.1794974</article-id><article-id pub-id-type="publisher-id">1794974</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of
Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Virtual screening, molecular dynamics and structure&#x02013;activity relationship
studies to identify potent approved drugs for Covid-19 treatment</article-title><alt-title alt-title-type="left-running-head">M. M. Rahman et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Biomolecular Structure and
Dynamics</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6994-2598</contrib-id><name><surname>Rahman</surname><given-names>Md. Mahbubur</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Saha</surname><given-names>Titon</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Islam</surname><given-names>Kazi Jahidul</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Suman</surname><given-names>Rasel Hosen</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Biswas</surname><given-names>Sourav</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Rahat</surname><given-names>Emon Uddin</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Hossen</surname><given-names>Md. Rubel</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Islam</surname><given-names>Rajib</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Hossain</surname><given-names>Md Nayeem</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Mamun</surname><given-names>Abdulla Al</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Maksud</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Md Ackas</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1698-7044</contrib-id><name><surname>Halim</surname><given-names>Mohammad A.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0003">c</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Division of Infectious Diseases and Division
of Computer-Aided Drug Design, The Red-Green Research Centre, BICCB</institution>,
<city>Tejgaon</city>, <state>Dhaka</state>, <country>Bangladesh</country></aff><aff id="AF0002"><label>b</label><institution>Key Laboratory of Soft Chemistry and
Functional Materials of MOE, Department of Chemical Engineering, Nanjing University of
Science and Technology</institution>, <city>Nanjing</city>,
<country>China</country></aff><aff id="AF0003"><label>c</label><institution>Department of Physical Sciences, University of
Arkansas-Fort Smith</institution>, <city>Fort Smith</city>, <state>AR</state>,
<country>USA</country></aff></contrib-group><author-notes><fn id="AUFN2"><p>Supplemental data for this article can be accessed online at
https://doi.org/10.1080/07391102.2020.1794974</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Mohammad A. Halim
<email>mohammad.halim@uafs.edu</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>7</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><fpage seq="1">1</fpage><lpage>11</lpage><permissions><copyright-statement>&#x000a9; 2020 Informa UK Limited, trading as Taylor &#x00026; Francis
Group</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor &#x00026; Francis
Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted
re-use and analyses in any form or by any means with acknowledgement of the original
source. These permissions are granted for the duration of the COVID-19 pandemic or until
permissions are revoked in writing. Upon expiration of these permissions, PMC is granted
a perpetual license to make this article available via PMC and Europe PMC, consistent
with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TBSD_0_1794974.pdf"/><abstract><title>Abstract</title><p>Computer-aided drug screening by molecular docking, molecular dynamics (MD) and
structural&#x02013;activity relationship (SAR) can offer an efficient approach to identify
promising drug repurposing candidates for COVID-19 treatment. In this study, computational
screening is performed by molecular docking of 1615 Food and Drug Administration (FDA)
approved drugs against the main protease (Mpro) of SARS-CoV-2. Several promising approved
drugs, including Simeprevir, Ergotamine, Bromocriptine and Tadalafil, stand out as the
best candidates based on their binding energy, fitting score and noncovalent interactions
at the binding sites of the receptor. All selected drugs interact with the key active site
residues, including His41 and Cys145. Various noncovalent interactions including hydrogen
bonding, hydrophobic interactions, pi&#x02013;sulfur and pi&#x02013;pi interactions appear to be dominant
in drug&#x02013;Mpro complexes. MD simulations are applied for the most promising drugs.
Structural stability and compactness are observed for the drug&#x02013;Mpro complexes. The protein
shows low flexibility in both apo and holo form during MD simulations. The MM/PBSA binding
free energies are also measured for the selected drugs. For pattern recognition,
structural similarity and binding energy prediction, multiple linear regression (MLR)
models are used for the quantitative structural&#x02013;activity relationship. The binding energy
predicted by MLR model shows an 82% accuracy with the binding energy determined by
molecular docking. Our details results can facilitate rational drug design targeting the
SARS-CoV-2 main protease.</p><p>Communicated by Ramaswamy H. Sarma</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>FDA approved drug</kwd><kwd>structural&#x02013;activity relationship</kwd><kwd>molecular docking</kwd><kwd>molecular dynamics</kwd><kwd>principal component analysis</kwd></kwd-group><counts><fig-count count="7"/><table-count count="4"/><page-count count="11"/><word-count count="6556"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>A novel coronavirus was identified in Wuhan, China in December 2019 spreading an infectious
pneumonia-like disease (Huang et&#x000a0;al., <xref rid="CIT0020" ref-type="bibr">2020</xref>). The
International Committee on Taxonomy of Viruses (ICTV) named the novel coronavirus
(2019-nCoV) as SARS-CoV-2 (Gorbalenya et&#x000a0;al., <xref rid="CIT0018" ref-type="bibr">2020</xref>). The World Health Organization (WHO) officially named the disease caused by
SARS-CoV-2 as Coronavirus disease (COVID-19) on 11 February 2020. On the basis of &#x02018;alarming
levels of spread and severity, and by the alarming levels of inaction&#x02019;, on 11 March 2020,
the Director-General of WHO characterized the COVID-19 situation as a pandemic (Bedford
et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2020</xref>). To date, the total numbers of
reported cases have reached over 5 million and the number of death is more than 300 thousand
(Worldometer, <xref rid="CIT0046" ref-type="bibr">2020</xref>). Earlier, epidemics of severe
acute respiratory syndrome coronavirus (SARS-CoV) in Guangdong, China in 2003 and Middle
East respiratory syndrome coronavirus (MERS-CoV) in 2012 have shown a high fatality rate
(Hilgenfeld &#x00026; Peiris, <xref rid="CIT0019" ref-type="bibr">2013</xref>; Ton et&#x000a0;al., <xref rid="CIT0044" ref-type="bibr">2020</xref>). SARS-CoV-2 was found to be an enveloped
positive-sense, single- strained RNA virus belonging to the genus betacoronavirus (Beta-CoV)
(Chan et&#x000a0;al., <xref rid="CIT0005" ref-type="bibr">2020</xref>; Lu et&#x000a0;al., <xref rid="CIT0030" ref-type="bibr">2020</xref>). Phylogenetic analysis showed that SARS-CoV-2
is closely related to (with 88% identity) two bat-derived severe acute respiratory syndrome
(SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL- CoVZXC21, collected in 2018 in
Zhoushan, Eastern China, but are more distant from SARS-CoV (about 79%) and MERS-CoV (about
50%) (Lu et&#x000a0;al., <xref rid="CIT0030" ref-type="bibr">2020</xref>). CoVs have the largest
known RNA virus genomes, ranging from 27 to 34&#x02009;kb (Sexton et&#x000a0;al., <xref rid="CIT0039" ref-type="bibr">2016</xref>).</p><p>Inside the host cell, coronavirus genomes are translated into two groups of proteins;
structural proteins, such as Spike (S), Envelope (E), Matrix (M) and Nucleocapsid (N) and
nonstructural proteins, such as 3C-Like Protease (3CL-PRO, nsp5), RNA Dependent RNA
Polymerase (RdRp, nsp12) (Elfiky, <xref rid="CIT0014" ref-type="bibr">2020</xref>).
Coronavirus genome replication and transcription takes place at cytoplasmic membranes and
involves a coordinated process of both continuous and discontinuous RNA synthesis that is
mediated by the viral replicate (Sola et&#x000a0;al., <xref rid="CIT0041" ref-type="bibr">2015</xref>). The main protease (Mpro) of SARS-CoV-2 plays an important role in cutting
down polyproteins into functional pieces (Chen et&#x000a0;al., <xref rid="CIT0007" ref-type="bibr">2020</xref>; Shaghaghi, <xref rid="CIT0040" ref-type="bibr">2020</xref>). Thus, the main
protease plays a vital role in viral replication. The main protease (also known as 3C-like
protease) can be an attractive drug target to inhibit coronavirus. Inhibiting the activity
of the main protease could block the replication of the virus inside infected cells.</p><p>The crystallized structure of the main protease (Mpro) or Chymotrypsin-like protease
(3CL-Pro) of SARS-CoV-2 was identified and repositioned at the RCSB Protein Data bank (PDB)
(Jin et&#x000a0;al., <xref rid="CIT0024" ref-type="bibr">2020</xref>). The crystallized structure
(PDB ID: 6LU7) contains two chains, A and B, which form a homodimer. Chain A was used for
macromolecule preparation. The protein chain is composed of 306 residues. His41 and Cys145
form an uncharged catalytic dyad (Paasche et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2014</xref>). The active site of the protease is activated by a protonation reaction in
the catalytic site (Paasche et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2014</xref>).
Inhibiting the activity of the catalytic dyad will ultimately help to inhibit the activity
of the main protease.</p><p>Currently, no effective drugs targeting SARS-CoV-2 are available. Drug repurposing, a
strategy to identify new uses of approved drugs, could shorten the time and reduce the cost
for identifying effective drugs against COVID-19 (Zhou et&#x000a0;al., <xref rid="CIT0048" ref-type="bibr">2020</xref>). We have selected 1615 FDA approved drugs from the ZINC
database (Irwin &#x00026; Shoichet, <xref rid="CIT0021" ref-type="bibr">2005</xref>). The focus
of this study is to identify the binding affinities and molecular interactions of these
drugs against the main protease using computational and statistical tools. Molecular
docking, molecular dynamics (MD), principal components analysis (PCA) and quantitative
structure&#x02013;activity relationships (QSAR) were executed to evaluate the performance of the
drugs.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Computational methods</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Virtual screening and molecular docking protocols</title><p>The structures of 1615 FDA approved drugs are obtained from the ZINC database. The
database was then checked for redundant molecules. The three-dimensional crystal structure
of SARS-CoV-2 main protease (Mpro,3CL<sup>pro</sup>) was collected from the RCSB Protein
Data Bank (PDB) database (PDB-ID:6LU7, Resolution = 2.16&#x02009;&#x000c5;, Method: X-ray diffraction,
Organism: Bat-SARS like coronavirus) (Zhang et&#x000a0;al., <xref rid="CIT0047" ref-type="bibr">2020</xref>). The crystal structure of Mpro was prepared according to previously
published methods for molecular docking (Islam et&#x000a0;al., <xref rid="CIT0023" ref-type="bibr">2020</xref>). Potential active site residues were specified by their vicinity to the
ligand, N3 (Sekhar, <xref rid="CIT0038" ref-type="bibr">2020</xref>). PyRx Virtual
Screening Tools incorporated with Autodock Vina was used for virtual screening (Dallakyan
&#x00026; Olson, <xref rid="CIT0011" ref-type="bibr">2015</xref>). Structural optimization of
the drugs was carried out with universal force field (UFF) using the steepest descent
optimization algorithm, a total of 2000 minimization steps (Ahmed et&#x000a0;al., <xref rid="CIT0001" ref-type="bibr">2020</xref>). These drugs were converted to AutoDock
ligand (PDBQT format) for docking. The grid center points were set to <italic>X</italic> = &#x02212;11.5693, <italic>Y</italic>&#x02009;=&#x02009;14.9663, <italic>Z</italic>&#x02009;=&#x02009;67.9041 and box dimensions (Angstrom) <italic>X</italic>&#x02009;=&#x02009;34.6857, <italic>Y</italic>&#x02009;=&#x02009;45.2264, <italic>Z</italic>&#x02009;=&#x02009;42.8980. Grid box center points and dimensions were set to target the
substrate binding-binding pocket of the protein (Chen et&#x000a0;al., <xref rid="CIT0006" ref-type="bibr">2006</xref>). The binding affinities of the drugs were measured in
kcal/mol unit and sorted according to the higher negative values, which imply the best
binding affinities (de Sousa et&#x000a0;al., <xref rid="CIT0012" ref-type="bibr">2020</xref>).
Based on calculated binding affinities, the 31 top-ranked potential drugs were chosen for
further analysis. The top-ranked drugs were then optimized by Gaussian 09 software using
semi-empirical PM6 method (Frisch, <xref rid="CIT0600" ref-type="bibr">2009</xref>). These
optimized drug structures are then docked again using AutoDock Vina software and GOLD
(Jones et&#x000a0;al., <xref rid="CIT0025" ref-type="bibr">1997</xref>) docking programs. The
molecular interactions of the drugs as predicted by docking simulation were analyzed in
BIOVIA Discovery Studio Visualizer (Studio, <xref rid="CIT0042" ref-type="bibr">2015</xref>).</p></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>MD simulation protocols</title><p>The MD simulations for the main protease were conducted (6LU7) in apo-form (protein
without ligand) and in holo-form (protein&#x02013;drug complex) to assess any probable
conformational changes to and interactions with their structures over the 100 nanoseconds
(ns). AMBER14 force field (Dickson et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2014</xref>) was used on YASARA Dynamics (Krieger et&#x000a0;al., <xref rid="CIT0027" ref-type="bibr">2013</xref>) for the simulation. Water molecules were added and the system
was neutralized by the addition of NaCl salt of 0.9% concentration at a temperature of
310&#x02009;K (Krieger et&#x000a0;al., <xref rid="CIT0028" ref-type="bibr">2006</xref>). The particle-mesh
Ewald method was used for calculating long-range electrostatic interactions. A periodic
boundary condition was utilized to carry out the simulation. In all cases, the cell size
was larger than the protein by 20&#x02009;&#x000c5;. The temperature of the simulation was controlled by
the Berendsen thermostat. The initial energy minimization process of each simulation was
performed by the simulated annealing method, using the steepest gradient approach (5000
cycles). Normal simulation speed (1.25 fs time step) was maintained during all the
simulations (Krieger &#x00026; Vriend, <xref rid="CIT0029" ref-type="bibr">2015</xref>). A
snapshot was saved in every 100&#x02009;ps during simulations. After completion of 100&#x02009;ns MD
simulation for all systems, the results were analyzed in YASARA. During the analysis of
the simulations, time, energy, bond distances, bond angles, dihedral angles,
solvent&#x02013;accessible surface area (SASA), molecular surface area (MolSA), coulombic and Van
der Waals interactions, root mean square fluctuation (RMSF) and root mean square deviation
(RMSD) values for backbone, alpha carbon and heavy atoms were recorded. For more accuracy,
the 100&#x02009;ns MD simulation was conducted twice for every complex and the average result was
used for analysis.</p><p>For binding free energy calculations, molecular mechanics/Poisson&#x02013;Boltzmann surface area
(MM/PBSA) method was used in YASARA Dynamics software (Baker et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2001</xref>; Chirag et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2020</xref>; Massova &#x00026; Kollman, <xref rid="CIT0033" ref-type="bibr">2000</xref>).
The AMBER14 force field was used during the binding free energy calculation. The default
macro file was modified for the calculation. The following equation was used for the
binding free energy calculation: <disp-formula id="M0001"><alternatives><graphic xlink:href="TBSD_A_1794974_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d1e376"><mml:mrow><mml:mo>&#x00394;</mml:mo><mml:mi>G</mml:mi><mml:mtext>bind</mml:mtext><mml:mo>=</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mi>G</mml:mi><mml:msub><mml:mrow><mml:mrow><mml:mtext>complex</mml:mtext></mml:mrow></mml:mrow><mml:mo stretchy="false">(</mml:mo></mml:msub><mml:msub><mml:mrow/><mml:mrow><mml:mtext>minimized</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02013;</mml:mo><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mo>&#x00394;</mml:mo><mml:mi>G</mml:mi><mml:msub><mml:mrow><mml:mrow><mml:mtext>ligand</mml:mtext></mml:mrow></mml:mrow><mml:mo stretchy="false">(</mml:mo></mml:msub><mml:msub><mml:mrow/><mml:mrow><mml:mtext>minimized</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mi>G</mml:mi><mml:msub><mml:mrow><mml:mrow><mml:mtext>receptor</mml:mtext></mml:mrow></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>minimized</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="M0002"><alternatives><graphic xlink:href="TBSD_A_1794974_M0002.jpg" position="float" orientation="portrait"/><mml:math id="d1e436"><mml:mrow><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>&#x00394;</mml:mi></mml:mstyle><mml:mi>G</mml:mi><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mstyle><mml:mo>=</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>&#x00394;</mml:mi></mml:mstyle><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>M</mml:mi><mml:mi>M</mml:mi></mml:mstyle></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>&#x00394;</mml:mi></mml:mstyle><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>P</mml:mi><mml:mi>B</mml:mi></mml:mstyle></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>&#x00394;</mml:mi></mml:mstyle><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>S</mml:mi><mml:mi>A</mml:mi></mml:mstyle><mml:mo>&#x02212;</mml:mo><mml:mi>T</mml:mi><mml:mi>&#x00394;</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></disp-formula>
</p><p>Here, &#x00394;<italic>G</italic><sub>MM</sub> is the molecular mechanics
interaction (sum of electrostatic and van der Waals interaction), &#x00394;<italic>G</italic><sub>PB</sub> and &#x00394;<italic>G</italic><sub>SA</sub> correspond to
polar and nonpolar solvation energyies, respectively. <italic>T&#x00394;S</italic> is
the entropic contribution. Due to the high computational time, the entropy contribution
was not considered. The final 50&#x02009;ns data of MD simulation was used for binding free energy
calculations.</p><p>Principal component analysis (PCA) is applied to identify similarities and
dissimilarities among the collected energy profiles of MD trajectory data (Martens &#x00026;
Naes, <xref rid="CIT0032" ref-type="bibr">1998</xref>). The important components of a PCA
model are highlighted in the following equation: <italic>X&#x02009;=&#x02009;T<sub>k</sub>P<sub>k</sub><sup>T</sup> + E</italic>, where the <italic>X</italic> matrix expresses a product of two new matrices, i.e. <italic>T<sub>k</sub></italic>, <italic>P<sub>k</sub></italic>,
<italic>T<sub>k</sub></italic> is the matrix of scores that shows how
samples relate to each other, <italic>P<sub>k</sub></italic> is the matrix of
loadings, which carries information about how the variables relate to each other, <italic>k</italic> represents the number of factors involved in the model and
<italic>E</italic> is the matrix of residuals.</p><p>The selected four drug&#x02013;main protease complexes may have dissimilarities with the apo&#x02013;Mpro
during MD simulation regarding the energy profile. These dissimilarities can be identified
using the PCA algorithm (Islam et al., <xref rid="CIT0022" ref-type="bibr">2019</xref>,
<xref rid="CIT0023" ref-type="bibr">2020</xref>). All calculations were carried out on R
platform employing in-house developed codes and plots were produced using the package
ggplot2 (Kassambara, <xref rid="CIT0026" ref-type="bibr">2016</xref>). Data were
preprocessed employing autoscale function before applying the PCA algorithm (Martens &#x00026;
Naes, <xref rid="CIT0032" ref-type="bibr">1998</xref>). The last 40&#x02009;ns data of the MD
trajectory was utilized for PCA.</p></sec><sec id="S0002-S2003" disp-level="2"><label>2.3.</label><title>Structure&#x02013;activity relationship protocols</title><p>Structure&#x02013;activity relationship (SAR) is a method for establishing computational or
mathematical models that aim to detect a statistically significant correlation between
structure and function employing chemometric technique (Verma et&#x000a0;al., <xref rid="CIT0045" ref-type="bibr">2010</xref>). 31 initially selected drugs are explored in
this study. Topological polar surface area (TPSA, &#x000c5;<sup>2</sup>), molecular weight (MW,
gmol<sup>&#x02212;1</sup>), XLogP3-AA, hydrogen bond donor (HBD), hydrogen bond acceptor (HBA),
number of the rotatable bonds (ROTB), number of H, C, O, Cl, F atoms, single bonds (SB)
count, number of double bonds (DB) and number of benzene rings of the drug candidates were
studied as variables. Along with calculated binding energies, these variables were applied
to correlate with the SAR by multiple linear regression (MLR) (Fakayode et&#x000a0;al., <xref rid="CIT0015" ref-type="bibr">2009</xref>; Mark &#x00026; Workman, <xref rid="CIT0031" ref-type="bibr">2007</xref>). MLR was carried out with XLSTAT (Adinsoft, <xref rid="CIT0700" ref-type="bibr">2010</xref>).</p></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Results and discussions</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Virtual screening and molecular docking</title><p>The structure of 1615 FDA approved drugs is considered for virtual screening using
Autodock Vina. Considering &#x02212;5.1&#x02009;kcal/mol as a cutoff value, the binding affinities of the
drugs are distributed between &#x02212;5.1 to &#x02212;6.0, &#x02212;6.1 to &#x02212;7.0, &#x02212;7.1 to &#x02212;8.0, &#x02212;8.1 to &#x02212;9.0 and
&#x02212;9.1 to &#x02212;10.4&#x02009;kcal/mol (<xref ref-type="fig" rid="F0001">Figure 1</xref>). Most drugs are
found to have binding affinities between &#x02212;6.1 to &#x02212;7.0&#x02009;kcal/mol. The top 31 candidates are
selected for further analysis according to their binding affinities. The binding affinity
of two already reported drugs Remdesivir and Lopinavir were observed &#x02212;7.5 and
&#x02212;7.4&#x02009;kcal/mol, respectively. After optimizing by PM6 level of theory, the selected drugs
are screened again in AutoDock Vina. GOLD suit was also employed to understand the binding
fitness using the CHEMPLP fitness score. Here, a higher fitness score suggests better
docking interaction between protein and ligand. Along with 5 previously suggested FDA
approved drugs (Contini, <xref rid="CIT0010" ref-type="bibr">2020</xref>), the binding
affinities and GOLD fitting scores of 31 drugs are summarized in <xref rid="t0001" ref-type="table">Table 1</xref>. According to best binding affinities, Simeprevir,
Ergotamine, Bromocriptine and Tadalafil are selected for further analysis (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Remdesivir and Lopinavir are also
considered as control drugs for MD simulations.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Frequency distribution of FDA approved drugs over the range of docking score (Cutoff
value &#x02013;5.1&#x02009;kcal/mol).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794974_F0001_C"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Two dimensional (2D) structures of the selected drugs.</p></caption><graphic content-type="black-white" xlink:href="TBSD_A_1794974_F0002_B"/></fig><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>AutoDock Vina predicted binding affinity (kcal/mol) and GOLD fitting score of 31
drugs and 5 already reported drugs with SARS-CoV-2 Mpro.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Drug</th><th align="center">Binding affinity
(kcal/mol)</th><th align="center">GOLD fitting score</th></tr></thead><tbody valign="top"><tr><td align="left">Simeprevir</td><td rowspan="2" align="center">&#x02013;10.3</td><td rowspan="2" align="char" char=".">73.83</td></tr><tr><td align="left">ZINC000164760756</td></tr><tr><td align="left">Ergotamine</td><td rowspan="2" align="center">&#x02013;9.8</td><td rowspan="2" align="char" char=".">81.8</td></tr><tr><td align="left">ZINC000052955754</td></tr><tr><td align="left">Bromocriptine</td><td rowspan="2" align="center">&#x02013;9.6</td><td rowspan="2" align="char" char=".">70.66</td></tr><tr><td align="left">ZINC000053683151</td></tr><tr><td align="left">Tadalafil</td><td rowspan="2" align="center">&#x02013;9.5</td><td rowspan="2" align="char" char=".">59.32</td></tr><tr><td align="left">ZINC000003993855</td></tr><tr><td align="left">Dihydroergotamine</td><td rowspan="2" align="center">&#x02013;9.2</td><td rowspan="2" align="char" char=".">75.46</td></tr><tr><td align="left">ZINC000003978005</td></tr><tr><td align="left">Perampanel</td><td rowspan="2" align="center">&#x02013;9.2</td><td rowspan="2" align="char" char=".">74.57</td></tr><tr><td align="left">ZINC000030691797</td></tr><tr><td align="left">Nilotinib</td><td rowspan="2" align="center">&#x02013;9.2</td><td rowspan="2" align="char" char=".">84.77</td></tr><tr><td align="left">ZINC000006716957</td></tr><tr><td align="left">Rolapitant</td><td rowspan="2" align="center">&#x02013;9.1</td><td rowspan="2" align="char" char=".">72.66</td></tr><tr><td align="left">ZINC000003816514</td></tr><tr><td align="left">Naldemedine</td><td rowspan="2" align="center">&#x02013;8.9</td><td rowspan="2" align="char" char=".">70.68</td></tr><tr><td align="left">ZINC000100378061</td></tr><tr><td align="left">Irinotecan ZINC000001612996</td><td align="center">&#x02013;8.9</td><td align="center">72.3</td></tr><tr><td align="left">Raltegravir</td><td rowspan="2" align="center">&#x02013;8.9</td><td rowspan="2" align="char" char=".">64.33</td></tr><tr><td align="left">ZINC000013831130</td></tr><tr><td align="left">Lumacaftor</td><td rowspan="2" align="center">&#x02013;8.8</td><td rowspan="2" align="char" char=".">68.84</td></tr><tr><td align="left">ZINC000064033452</td></tr><tr><td align="left">Eltrombopag</td><td rowspan="2" align="center">&#x02013;8.8</td><td rowspan="2" align="char" char=".">69.34</td></tr><tr><td align="left">ZINC000011679756</td></tr><tr><td align="left">Saquinavir</td><td rowspan="2" align="center">&#x02013;8.7</td><td rowspan="2" align="char" char=".">87.79</td></tr><tr><td align="left">ZINC000003914596</td></tr><tr><td align="left">Sildenafil</td><td rowspan="2" align="center">&#x02013;8.7</td><td rowspan="2" align="char" char=".">80.21</td></tr><tr><td align="left">ZINC000019796168</td></tr><tr><td align="left">Pimozide</td><td rowspan="2" align="center">&#x02013;8.6</td><td rowspan="2" align="char" char=".">77.44</td></tr><tr><td align="left">ZINC000004175630</td></tr><tr><td align="left">Paliperidone</td><td rowspan="2" align="center">&#x02013;8.5</td><td rowspan="2" align="char" char=".">62.18</td></tr><tr><td align="left">ZINC000004214700</td></tr><tr><td align="left">Suvorexant</td><td rowspan="2" align="center">&#x02013;8.5</td><td rowspan="2" align="char" char=".">62.23</td></tr><tr><td align="left">ZINC000049036447</td></tr><tr><td align="left">Nintedanib</td><td rowspan="2" align="center">&#x02013;8.5</td><td rowspan="2" align="char" char=".">79.48</td></tr><tr><td align="left">ZINC000100014909</td></tr><tr><td align="left">Maraviroc</td><td rowspan="2" align="center">&#x02013;8.5</td><td rowspan="2" align="char" char=".">74.25</td></tr><tr><td align="left">ZINC000100003902</td></tr><tr><td align="left">Paliperidone</td><td rowspan="2" align="center">&#x02013;8.4</td><td rowspan="2" align="char" char=".">58.75</td></tr><tr><td align="left">ZINC000001481956</td></tr><tr><td align="left">Conivaptan</td><td rowspan="2" align="center">&#x02013;8.4</td><td rowspan="2" align="char" char=".">69.76</td></tr><tr><td align="left">ZINC000012503187</td></tr><tr><td align="left">Pazopanib</td><td rowspan="2" align="center">&#x02013;8.4</td><td rowspan="2" align="char" char=".">66.93</td></tr><tr><td align="left">ZINC000011617039</td></tr><tr><td align="left">Ibrutinib</td><td rowspan="2" align="center">&#x02013;8.4</td><td rowspan="2" align="char" char=".">76.69</td></tr><tr><td align="left">ZINC000035328014</td></tr><tr><td align="left">Tipranavir</td><td rowspan="2" align="center">&#x02013;8.4</td><td rowspan="2" align="char" char=".">79.31</td></tr><tr><td align="left">ZINC000100022637</td></tr><tr><td align="left">Dabrafenib ZINC000068153186</td><td align="center">&#x02013;8.3</td><td align="center">68.28</td></tr><tr><td align="left">Telotristat</td><td rowspan="2" align="center">&#x02013;8.3</td><td rowspan="2" align="char" char=".">74.89</td></tr><tr><td align="left">ZINC000084758235</td></tr><tr><td align="left">Teniposide</td><td rowspan="2" align="center">&#x02013;8.2</td><td rowspan="2" align="char" char=".">58.82</td></tr><tr><td align="left">ZINC000004099009</td></tr><tr><td align="left">Apixaban</td><td rowspan="2" align="center">&#x02013;8.2</td><td rowspan="2" align="char" char=".">72.74</td></tr><tr><td align="left">ZINC000011677837</td></tr><tr><td align="left">Rifaximin</td><td rowspan="2" align="center">&#x02013;7.7</td><td rowspan="2" align="char" char=".">42.56</td></tr><tr><td align="left">ZINC000169621200</td></tr><tr><td align="left">Lifitegrast</td><td rowspan="2" align="center">&#x02013;7.5</td><td rowspan="2" align="char" char=".">73.73</td></tr><tr><td align="left">ZINC000084668739</td></tr><tr><td align="left">Montelukast (Contini, <xref ref-type="bibr" rid="CIT0010">2020</xref>)</td><td align="center">&#x02013;8.3</td><td align="center">93.62</td></tr><tr><td align="left">GHRP-2 (Contini, <xref ref-type="bibr" rid="CIT0010">2020</xref>)</td><td align="center">&#x02013;8.1</td><td align="center">95.49</td></tr><tr><td align="left">Indinavir (Contini, <xref ref-type="bibr" rid="CIT0010">2020</xref>)</td><td align="center">&#x02013;8</td><td align="center">88.35</td></tr><tr><td align="left">Cobicistat (Contini, <xref ref-type="bibr" rid="CIT0010">2020</xref>)</td><td align="center">&#x02013;7.5</td><td align="center">86.53</td></tr><tr><td align="left">Angiotensin II (Contini, <xref ref-type="bibr" rid="CIT0010">2020</xref>)</td><td align="center">&#x02013;6.9</td><td align="center">89.85</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Molecular interactions of the selected drugs with the main protease</title><p>Noncovalent interactions of the selected drugs which are detected by Autodock Vina
reveals that all of them interact with either both catalytic residues (His41 and Cys145)
or at least one of them, as shown in <xref ref-type="fig" rid="F0003">Figure 3</xref>.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Nonbonding interactions of top drug candidates with the main protease of SARS-CoV-2
(pose predicted by AutoDock Vina). (a) Simeprevir, (b) Ergotamine, (c) Bromocriptine,
and (d) Tadalafil.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794974_F0003_C"/></fig><p>Simeprevir, Ergotamine, Bromocriptine and Tadalafil form a number of hydrogen bonds and
hydrophobic interactions with the protein (noncovalent interactions detected by GOLD are
reported in <bold>(</bold><xref rid="t0002" ref-type="table">Table S2</xref>, supporting
information). Among them, most of the interactions with the active site residues are
categorized as hydrophobic (<xref rid="t0002" ref-type="table">Table 2</xref>). Both
Simeprevir and Ergotamine form a hydrogen bond with at least one of the catalytic
residues.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Noncovalent interactions of selected four drugs with main protease of SARS-CoV-2
(pose predicted by AutoDock Vina) where, H&#x02009;=&#x02009;Hydrogen bond, CH&#x02009;=&#x02009;Conventional Hydrogen
bond, C&#x02009;=&#x02009;Carbon Hydrogen bond.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Interacting residue</th><th align="center">Distance</th><th align="center">Bond category</th><th align="center">Bond type</th></tr></thead><tbody valign="top"><tr><td colspan="4"><bold>Simeprevir</bold></td></tr><tr><td align="left">CYS145</td><td align="char" char=".">2.7202</td><td align="left">H</td><td align="left">CH</td></tr><tr><td align="left">GLN189</td><td align="char" char=".">2.29</td><td align="left">H</td><td align="left">CH</td></tr><tr><td align="left">GLY143</td><td align="char" char=".">2.19455</td><td align="left">H</td><td align="left">CH</td></tr><tr><td align="left">THR190</td><td align="char" char=".">3.81766</td><td align="left">Hydrophobic</td><td align="left">Amide-Pi Stacked</td></tr><tr><td align="left">PRO168</td><td align="char" char=".">4.48443</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">LEU50</td><td align="char" char=".">5.06348</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">LEU50</td><td align="char" char=".">4.94019</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">PRO168</td><td align="char" char=".">4.58666</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">ALA191</td><td align="char" char=".">4.47775</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">PRO168</td><td align="char" char=".">3.91598</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td colspan="4"><bold>Ergotamine</bold></td></tr><tr><td align="left">HIS41</td><td align="char" char=".">2.88425</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">MET165</td><td align="char" char=".">1.89419</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">MET165</td><td align="char" char=".">4.81695</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">HIS41</td><td align="char" char=".">4.81113</td><td align="left">Hydrophobic</td><td align="left">Pi-Pi-T Shaped</td></tr><tr><td align="left">MET165</td><td align="char" char=".">5.65835</td><td align="left">Other</td><td align="left">Pi-sulfur</td></tr><tr><td colspan="4"><bold>Bromocriptine</bold></td></tr><tr><td align="left">GLY143</td><td align="char" char=".">2.32271</td><td align="left">H</td><td align="left">CH</td></tr><tr><td align="left">GLY143</td><td align="char" char=".">1.86614</td><td align="left">H</td><td align="left">CH</td></tr><tr><td align="left">ARG188</td><td align="char" char=".">2.28318</td><td align="left">H</td><td align="left">CH</td></tr><tr><td align="left">ASN142</td><td align="char" char=".">2.55112</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">GLY143</td><td align="char" char=".">2.91712</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">GLN189</td><td align="char" char=".">1.99597</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">LEU27</td><td align="char" char=".">3.98094</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">MET165</td><td align="char" char=".">5.33935</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">LEU27</td><td align="char" char=".">4.43789</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">CYS145</td><td align="char" char=".">3.95427</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">MET49</td><td align="char" char=".">4.83683</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">HIS41</td><td align="char" char=".">5.27854</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">MET165</td><td align="char" char=".">4.15194</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">MET165</td><td align="char" char=".">4.68951</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">GLN189</td><td align="char" char=".">2.38092</td><td align="left">Hydrophobic</td><td align="left">Pi-Sigma</td></tr><tr><td align="left">HIS41</td><td align="char" char=".">5.13653</td><td align="left">Hydrophobic</td><td align="left">Pi-Pi-T Shaped</td></tr><tr><td colspan="4"><bold>Tadalafil</bold></td></tr><tr><td align="left">ASN142</td><td align="char" char=".">2.16312</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">GLY143</td><td align="char" char=".">2.66564</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">MET165</td><td align="char" char=".">2.64728</td><td align="left">H</td><td align="left">C</td></tr><tr><td align="left">CYS145</td><td align="char" char=".">5.22621</td><td align="left">Hydrophobic</td><td align="left">Alkyl</td></tr><tr><td align="left">MET49</td><td align="char" char=".">5.50154</td><td align="left">Other</td><td align="left">Pi-Sulfur</td></tr><tr><td align="left">MET49</td><td align="char" char=".">5.03037</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">CYS145</td><td align="char" char=".">5.47403</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">MET49</td><td align="char" char=".">4.6017</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr><tr><td align="left">HIS41</td><td align="char" char=".">5.18874</td><td align="left">Hydrophobic</td><td align="left">Pi-Alkyl</td></tr></tbody></table></table-wrap><p>Simeprevir is observed to show three hydrophobic interactions with Pro168, two with Leu50
and one with each of the Thr190 and Ala191. Ergotamine exhibits one pi&#x02013;alkyl and one pi&#x02013;pi
T-shaped hydrophobic interaction with Met165 and His41, respectively. Among all the
protein&#x02013;drug complexes, Bromocriptine demonstrates the most noncovalent interactions with
the main protease. It shows two hydrophobic interactions with His41, two with Leu27, three
with Met165 and one with each of the Met49, Cys145 and Gln189 residues. Tadalafil exhibits
hydrophobic interactions with both catalytic residues. Both Ergotamine and Tadalafil show
one pi&#x02013;sulfur interaction with Met165 and Met49 residues, respectively.</p></sec><sec id="S0003-S2003" disp-level="2"><label>3.3.</label><title>MD simulation</title><p>MD simulation for all complexes of the main protease (6LU7) with the top four selected
drugs and apo&#x02013;form is performed for 100&#x02009;ns. RMSD of alpha carbon atoms, RMSF of all amino
acid residues, solvent accessible surface area, radius of gyration and the number of
hydrogen bonds of all the drug&#x02013;protein complexes and apo&#x02013;Mpro are investigated.</p><p>The RMSD of Simeprevir&#x02013;Mpro and Ergotamine&#x02013;Mpro are stabilized after 20&#x02009;ns of simulation,
with an average value of 1.81&#x02009;&#x000b1;&#x02009;0.30 &#x000c5; and 1.90&#x02009;&#x000b1;&#x02009;0.32 &#x000c5;, respectively (<xref rid="t0003" ref-type="table">Table 3</xref>). <xref ref-type="fig" rid="F0004">Figure
4a</xref> reveals that Bromocriptine&#x02013;Mpro follows a similar trend in MD trajectory like
apo&#x02013;Mpro. Tadalafil&#x02013;Mpro complex shows fluctuation until 30&#x02009;ns, while it reaches a peak of
3.01 &#x000c5; at 26.8&#x02009;ns. It exhibits structural stability after 30&#x02009;ns of MD simulation. These
drug&#x02013;Mpro complexes exhibit better stability in the RMSD trajectory than the control
drugs. Unstable nature is observed for the RMSD of Remdesivir&#x02013;Mpro after 70&#x02009;ns of MD
simulation, while the Lopinavir&#x02013;Mpro complex followed the similar trend like the
Bromocriptine&#x02013;Mpro complex. <xref ref-type="fig" rid="F0004">Figure 4b</xref> displays
root-mean-square fluctuation as a function of the residue number of the apo&#x02013;Mpro and
drug&#x02013;Mpro complexes. This is explored to understand how the binding of drug molecules
changes the behavior of the amino acid residues of the protein. A low RMSF is observed for
the apo&#x02013;Mpro which suggests low flexibility of protein even without a ligand. It also
shows flexibility at Ser46 to Asn53, Tyr154, Val303, Thr304, Phe305 and Gln306. The
residues Arg188 to Asp197 show high flexibility in Tadalafil&#x02013;Mpro complex. RMSF of
Simeprevir&#x02013;Mpro, Ergotamine&#x02013;Mpro, Bromocriptine&#x02013;Mpro, Remdesivir&#x02013;Mpro and Lopinavir&#x02013;Mpro
complexes are almost similar in most areas.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Analysis of RMSD, RMSF, SASA, <italic>R</italic><sub>g</sub> and total
number of hydrogen bonds of apo&#x02013;Mpro and selected four drug&#x02013;protein complexes at
100&#x02009;ns. (a) Root-mean-square deviation (RMSD, &#x000c5;) of the C&#x003b1; atoms over the phase of
100&#x02009;ns, (b) RMSF values of the alpha carbon over the entire simulation, where the
ordinate is RMSF (&#x000c5;), (c) Solvent accessible surface area (SASA), (d) Radius of
gyration (<italic>R</italic><sub>g</sub>) over the entire simulation, (e)
Total H-bond count throughout the simulation and (f) Binding Free Energy during the
last 50&#x02009;ns of simulation.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794974_F0004_C"/></fig><p>The radius of gyration (<italic>R</italic><sub>g</sub>) is the root mean
square distance of various atoms of a protein from the axis of rotation, and it
illustrates structural compactness. A greater change in <italic>R</italic><sub>g</sub> value may occur due to the folding or conformational changes of
protein structure, while a lower degree of fluctuation over the simulation period
indicates rigidity and higher compactness of a structure. According to the observed
<italic>R</italic><sub>g</sub> value, the apo&#x02013;Mpro and Simeprevir&#x02013;Mpro
complex showed almost similar structural compactness over the phase of the 100&#x02009;ns
simulation. The apo&#x02013;Mpro complex experienced a fluctuation in <italic>R</italic><sub>g</sub> value during 80&#x02013;90&#x02009;ns. Ergotamine showed structural compactness
all over the simulation time with an average of 22.32&#x02009;&#x000b1;&#x02009;0.11 &#x000c5;. Bromocriptine&#x02013;Mpro
followed a similar trend like the Remdesivir&#x02013;Mpro complex after 45&#x02009;ns. A loose packing is
observed for Tadalafil&#x02013;Mpro during 60&#x02009;ns to 90&#x02009;ns. Except for this time frame,
Tadalafil&#x02013;Mpro and Lopinavir&#x02013;Mpro followed a similar trend in MD trajectory. Based on the
overall <italic>R</italic><sub>g</sub>, the average values are 22.35&#x02009;&#x000b1;&#x02009;0.14
&#x000c5;, 22.39&#x02009;&#x000b1;&#x02009;0.14 &#x000c5;, 22.20&#x02009;&#x000b1;&#x02009;0.13 &#x000c5;, 22.57&#x02009;&#x000b1;&#x02009;0.24 &#x000c5;, 22.22&#x02009;&#x000b1;&#x02009;0.12 &#x000c5; and 22.42&#x02009;&#x000b1;&#x02009;0.11 &#x000c5; for
apo&#x02013;Mpro, Simeprevir&#x02013;Mpro, Bromocriptine&#x02013;Mpro, Tadalafil&#x02013;Mpro, Remdesivir&#x02013;Mpro and
Lopinavir&#x02013;Mpro complexes, respectively. To anticipate the solvent accessibility of all
complexes, the solvent-accessible surface area (SASA) of apo&#x02013;Mpro and complexes are
calculated (<xref ref-type="fig" rid="F0004">Figure 4(c)</xref>). Binding of a drug to the
protein may impact its structural properties, thus, SASA may also change. A higher SASA
value suggests the expansion of protein structure. A low fluctuation of SASA value is
expected during the simulation. All the examined complexes exhibit a similar trend until
40&#x02009;ns of MD trajectory. Simeprevir&#x02013;Mpro and Ergotamine&#x02013;Mpro showed lower SASA value than
the control drug&#x02013;Mpro complexes. The overall average SASA value suggests Lopinavir could
induce protein expansion, and thus, increase the solvent accessible surface of the protein
(<xref rid="t0003" ref-type="table">Table 3</xref>).</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Average RMSD, SASA, <italic>R</italic><sub>g</sub>, number of hydrogen
bonds and binding free energy of the selected drugs&#x02013;Mpro complexes.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Complex</th><th align="center">RMSD (&#x000c5;)</th><th align="center">SASA (&#x000c5;<sup>2</sup>)</th><th align="center">Radius of gyration (&#x000c5;)</th><th align="center">Number of hydrogen bonds</th><th align="center">Binding free energy
(kcal/mol)</th></tr></thead><tbody valign="top"><tr><td align="left">Apo&#x02013;Mpro</td><td align="char" char="&#x000b1;">2.07&#x02009;&#x000b1;&#x02009;0.32</td><td align="char" char="&#x000b1;">14137.41&#x02009;&#x000b1;&#x02009;217.54</td><td align="char" char="&#x000b1;">22.35&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char="&#x000b1;">510.2&#x02009;&#x000b1;&#x02009;11.80</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left">Simeprevir&#x02013;Mpro</td><td align="char" char="&#x000b1;">1.81&#x02009;&#x000b1;&#x02009;0.30</td><td align="char" char="&#x000b1;">13889.76&#x02009;&#x000b1;&#x02009;295.20</td><td align="char" char="&#x000b1;">22.39&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char="&#x000b1;">502&#x02009;&#x000b1;&#x02009;12.72</td><td align="char" char="&#x000b1;">&#x02013;77.44&#x02009;&#x000b1;&#x02009;2.43</td></tr><tr><td align="left">Ergotamine&#x02013;Mpro</td><td align="char" char="&#x000b1;">1.90&#x02009;&#x000b1;&#x02009;0.32</td><td align="char" char="&#x000b1;">13800.03&#x02009;&#x000b1;&#x02009;243.83</td><td align="char" char="&#x000b1;">22.32&#x02009;&#x000b1;&#x02009;0.11</td><td align="char" char="&#x000b1;">503.36&#x02009;&#x000b1;&#x02009;11.36</td><td align="char" char="&#x000b1;">&#x02013;26.33&#x02009;&#x000b1;&#x02009;0.39</td></tr><tr><td align="left">Bromocriptine&#x02013;Mpro</td><td align="char" char="&#x000b1;">2.07&#x02009;&#x000b1;&#x02009;0.36</td><td align="char" char="&#x000b1;">14035.29&#x02009;&#x000b1;&#x02009;208.71</td><td align="char" char="&#x000b1;">22.20&#x02009;&#x000b1;&#x02009;0.13</td><td align="char" char="&#x000b1;">512.50&#x02009;&#x000b1;&#x02009;12.33</td><td align="char" char="&#x000b1;">&#x02013;33.69&#x02009;&#x000b1;&#x02009;0.11</td></tr><tr><td align="left">Tadalafil&#x02013;Mpro</td><td align="char" char="&#x000b1;">2.24&#x02009;&#x000b1;&#x02009;0.41</td><td align="char" char="&#x000b1;">14197.53&#x02009;&#x000b1;&#x02009;390.24</td><td align="char" char="&#x000b1;">22.57&#x02009;&#x000b1;&#x02009;0.24</td><td align="char" char="&#x000b1;">510.86&#x02009;&#x000b1;&#x02009;14.66</td><td align="char" char="&#x000b1;">&#x02013;14.46&#x02009;&#x000b1;&#x02009;0.63</td></tr><tr><td align="left">Remdesivir&#x02013;Mpro</td><td align="char" char="&#x000b1;">1.89&#x02009;&#x000b1;&#x02009;0.36</td><td align="char" char="&#x000b1;">13892.51&#x02009;&#x000b1;&#x02009;252.63</td><td align="char" char="&#x000b1;">22.22&#x02009;&#x000b1;&#x02009;0.12</td><td align="char" char="&#x000b1;">507.96&#x02009;&#x000b1;&#x02009;12.04</td><td align="char" char="&#x000b1;">&#x02013;0.31&#x02009;&#x000b1;&#x02009;0.06</td></tr><tr><td align="left">Lopinavir&#x02013;Mpro</td><td align="char" char="&#x000b1;">2.03&#x02009;&#x000b1;&#x02009;0.41</td><td align="char" char="&#x000b1;">14168.63&#x02009;&#x000b1;&#x02009;226.90</td><td align="char" char="&#x000b1;">22.42&#x02009;&#x000b1;&#x02009;0.11</td><td align="char" char="&#x000b1;">508.66&#x02009;&#x000b1;&#x02009;12.10</td><td align="char" char="&#x000b1;">&#x02013;27.89&#x02009;&#x000b1;&#x02009;0.35</td></tr></tbody></table></table-wrap><p>Since intermolecular hydrogen bonds between protein&#x02013;drug complexes have a significant
contribution to the conformational stability of the complex, the total number of hydrogen
bonds is calculated (<xref ref-type="fig" rid="F0004">Figure 4(e)</xref>). The average
number of hydrogen bonds observed in apo&#x02013;Mpro is 510.2&#x02009;&#x000b1;&#x02009;11.80. The Bromocriptine&#x02013;Mpro
complex has the most hydrogen bonds over the 100&#x02009;ns simulation time (<xref rid="t0003" ref-type="table">Table 3</xref>).</p><p>Binding free energy calculations for each complex were conducted by employing the MM/PBSA
method. The Simeprevir&#x02013;Mpro shows the highest average binding free energy of
&#x02212;77.44&#x02009;&#x000b1;&#x02009;2.43&#x02009;kcal/mol. All our selected drug&#x02013;Mpro complexes demonstrate better binding
free energy than the Remdesivir&#x02013;Mpro complex (<xref ref-type="fig" rid="F0004">Figure
4(f)</xref><bold>)</bold>. The binding free energy of the Remdesivir&#x02013;Mpro complex
persisted as positive most of the time, which indicates loose binding between the drug and
the protein. The binding free energy of Ergotamine&#x02013;Mpro, Bromocriptine&#x02013;Mpro,
Tadalafil&#x02013;Mpro and Lopinavir&#x02013;Mpro complexes remained negative most of the time, which also
indicates good binding (<xref ref-type="fig" rid="F0002">Figure S2</xref>, supporting
information). The average binding free energy was observed &#x02212;26.33&#x02009;&#x000b1;&#x02009;0.39, &#x02212;33.69&#x02009;&#x000b1;&#x02009;0.11,
&#x02212;14.46&#x02009;&#x000b1;&#x02009;0.63, &#x02212;0.31&#x02009;&#x000b1;&#x02009;0.06 and &#x02212;27.89&#x02009;&#x000b1;&#x02009;0.35&#x02009;kcal/mol for Ergotamine, Bromocriptine,
Tadalafil, Remdesivir and Lopinavir, respectively.</p><p>The snapshots of Mpro&#x02013;drug complexes are visualized at different time intervals to
explore the drugs pose during MD simulation. All our selected drugs stayed at the binding
pocket of the protein over the phase of 100&#x02009;ns MD simulation (<xref ref-type="fig" rid="F0005">Figure 5</xref>). Additionally, all drugs interact with at least one of the
catalytic residues during most of the time of MD simulation (Table S4, supporting
information).</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Binding pose of drugs during 100&#x02009;ns MD simulation. The crystal structure of Mpro is
shown in beige color with (a) Simeprevir (cyan), (b) Ergotamine (green), (c)
Bromocriptine (blue) and (d) Tadalafil (orange red).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794974_F0005_C"/></fig></sec><sec id="S0003-S2004" disp-level="2"><label>3.4.</label><title>Principal components analysis</title><p>PCA is applied to observe the structural properties and energy profiles of apo&#x02013;Mpro and
the selected four drug&#x02013;Mpro complexes. A single PCA model consisting of five training sets
(Mpro and four drug&#x02013;Mpro complexes) was constructed for analysis. The first two PCs
explained 91.74% of the total variance, where PC1 contributed 75.07% and PC2 contributed
16.67% of the variance. It is observed from the scores plot (<xref ref-type="fig" rid="F0006">Figure 6(a)</xref>) that the apo&#x02013;Mpro (violet) and Simeprevir&#x02013;Mpro complex
(cyan) overlap with each other, thus, indicating similarity in energy and structural
profile. Moreover, Ergotamine&#x02013;Mpro (green) and Tadalafil&#x02013;Mpro (orange&#x02013;red) shifted
slightly toward the right in the PC1 direction and resided very close to apo&#x02013;Mpro and
Simeprevir&#x02013;Mpro complex. Thus, by forming a complex with Ergotamine and Tadalafil, Mpro
showed a similar structural profile compared to Mpro alone. However, the
Bromocriptine&#x02013;Mpro complex (blue) shifted significantly toward the positive direction of
PC1. This indicates greater dissimilarity of Bromocriptine&#x02013;Mpro with apo&#x02013;Mpro and other
complexes. The loading plot (<xref ref-type="fig" rid="F0006">Figure 6(b)</xref>) revealed
that the variables are separated in the PC1 direction, which explains different cluster
formation in the PC1 direction. Therefore, it is evident from the PCA scoring plot that
Simeprevir has the best binding stability with Mpro, while Ergotamine and Tadalafil also
demonstrate almost similar behavior in MD simulation.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>(a) The score plot presented five data clusters in different color, where each dot
represents one time point. The clustering is attributable as: apo&#x02013;Mpro (violet),
Simeprevir&#x02013;Mpro complex (cyan), Ergotamine&#x02013;Mpro (green), Bromocriptine&#x02013;Mpro (blue),
Tadalafil&#x02013;Mpro (orange red) (b) loading plot from principal components analysis of the
energy and structural data.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794974_F0006_C"/></fig></sec><sec id="S0003-S2005" disp-level="2"><label>3.5.</label><title>Structure&#x02013;activity relationship</title><p>SAR has been used for decades by researchers as a cheaper way to develop relationships
between physiochemical properties of chemicals and their bioactivities (Santos-Filho
et&#x000a0;al., <xref rid="CIT0037" ref-type="bibr">2009</xref>; Verma et&#x000a0;al., <xref rid="CIT0045" ref-type="bibr">2010</xref>). It is a widely used tool in bioinformatics,
drug discovery for clinical research, pharmaceutical industry, petrochemical and
agrochemical sectors for modeling and predictive pattern analysis (Alam &#x00026; Khan, <xref rid="CIT0002" ref-type="bibr">2017</xref>; Fakayode et&#x000a0;al., <xref rid="CIT0016" ref-type="bibr">2014</xref>; Funar-Timofei et&#x000a0;al., <xref rid="CIT0017" ref-type="bibr">2017</xref>). For further analysis, MLR has been employed. For instance, TPSA
(&#x000c5;<sup>2</sup>), molecular weight, XLogP3, H-bond donor count, H-bond acceptor count of
the drugs are the most significant variables on QSAR contributors to the MLR model (<xref rid="t0003" ref-type="table">Table S3</xref>, supporting information<bold>)</bold>.</p><p>The drugs with similar functional groups are found to stay side by side on the score plot
<bold>(</bold><xref ref-type="fig" rid="F0007">Figure 7</xref>). For example, drugs (D2,
D3 and D5) containing indole ring, amide group and alcohol group are clustered together on
the fourth quadrant of the score plot. On the other hand, drugs (D23, D7, D16, D13, D22
and D24) with diazole ring attached to the benzene ring are clustered on the second and
third quadrants. The grouping on the score plot was highly significant.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Score plot of PCA analysis for quantitative structural&#x02013;activity relationship of
drugs.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1794974_F0007_C"/></fig><p>The MLR model is generated and employed to predict the binding energy obtained from
molecular docking. Additionally, a test set is utilized for the validation of drug
candidates. The observed results of validation reveal similarity in the binding energies
(<xref rid="t0004" ref-type="table">Table 4</xref>).</p><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Predicted binding energy by the MLR model and actual binding energy from molecular
docking.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Sample</th><th align="center">Predicted binding energy
(kcal/mol)</th><th align="center">Actual binding
energy(kcal/mol)</th><th align="center">%RE</th></tr></thead><tbody valign="top"><tr><td align="left">D2</td><td align="center">&#x02013;8.89</td><td align="center">&#x02013;9.80</td><td align="center">&#x02013;2.99</td></tr><tr><td align="left">D5</td><td align="center">&#x02013;8.92</td><td align="center">&#x02013;9.20</td><td align="center">&#x02013;0.91</td></tr><tr><td align="left">D8</td><td align="center">&#x02013;8.90</td><td align="center">&#x02013;9.10</td><td align="center">&#x02013;0.66</td></tr><tr><td align="left">D12</td><td align="center">&#x02013;8.76</td><td align="center">&#x02013;8.80</td><td align="center">&#x02013;0.13</td></tr><tr><td align="left">D15</td><td align="center">&#x02013;8.99</td><td align="center">&#x02013;8.70</td><td align="center">0.98</td></tr><tr><td align="left">D20</td><td align="center">&#x02013;9.03</td><td align="center">&#x02013;8.50</td><td align="center">1.77</td></tr><tr><td align="left">D24</td><td align="center">&#x02013;8.68</td><td align="center">&#x02013;8.40</td><td align="center">0.92</td></tr><tr><td align="left">D26</td><td align="center">&#x02013;8.62</td><td align="center">&#x02013;8.30</td><td align="center">1.07</td></tr><tr><td align="left">D28</td><td align="center">&#x02013;9.02</td><td align="center">&#x02013;8.20</td><td align="center">2.72</td></tr><tr><td align="left">D29</td><td align="center">&#x02013;8.77</td><td align="center">&#x02013;8.20</td><td align="center">1.90</td></tr><tr><td align="left">D31</td><td align="center">&#x02013;8.64</td><td align="center">&#x02013;7.50</td><td align="center">3.79</td></tr><tr><td align="left"><bold><italic toggle="yes">RMS%RE</italic></bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center"><bold><italic toggle="yes">1.95</italic></bold></td></tr></tbody></table></table-wrap><p>The ability of the MLR model to accurately anticipate the binding energy of the validated
drugs is evaluated by the root-mean-square-relative percent-error (RMS%RE). The result
obtained from MLR is 82% accurate while comparing to the binding energy. Yet, findings
from this analysis can help researchers predict the drug performances against the main
protease considering the binding energy, chemical behavior and pharmacological efficacy of
upcoming drug candidates.</p></sec></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Conclusion</title><p>In this study, several computational and statistical tools such as molecular docking, MD
simulation, SAR and PCA are used to detect the best existing drugs against the main protease
of SARS-CoV-2. Among the 1615 studied drugs, Simeprevir, Ergotamine, Bromocriptine and
Tadalafil are found to have the highest binding affinity. As these drugs are already
certified for human use, they do not require long-term clinical trials. These drugs show a
significant number of noncovalent interactions including hydrogen bond, hydrophobic
interaction and electrostatic interaction with the binding site residues of Mpro. All the
selected drugs interact either with both (His41 and Cys145) or at least one of the catalytic
residues. Furthermore, MD simulations exhibit that Simeprevir, Ergotamine and Bromocriptine
drugs with Mpro protein preserve the structural stability over the simulation period.
Additionally, the MM/PBSA free energy profiles of these drugs suggest strong binding with
the receptor. SAR pattern recognition reveals that drugs containing an indole ring, amide
group and alcohol group are clustered together in the fourth quadrant and drugs containing
an azole ring attached to benzene ring are assembled together in the second and third
quadrant of the scoring plot. The predicted binding affinity values from MLR shows 82%
accuracy compared to values obtained from molecular docking. It can be concluded that the
selected drugs are promising and can be used to design effective drugs against the
SARS-CoV-2.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM5610"><caption><title>Supplemental Material</title></caption><media xlink:href="TBSD_A_1794974_SM5610.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We are grateful to our donors (<ext-link ext-link-type="uri" xlink:href="http://grc-bd.org/donate/">http://grc-bd.org/donate/</ext-link>) who supported
the building of the computational platform in Bangladesh. The authors acknowledge the World
Academy of Science (TWAS) for purchasing the High-Performance computer for the MD
simulations.</p></ack><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0700"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Adinsoft, S. (</collab></person-group><year>2010</year>). XLSTAT-software,
version 10. Addinsoft.</mixed-citation></ref><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Shahinozzaman</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fakayode</surname><given-names>S. O.</given-names></name>,
<name name-style="western"><surname>Afrin</surname><given-names>N.</given-names></name>, &#x00026; <name name-style="western"><surname>Halim</surname><given-names>M.
A.</given-names></name></person-group> (<year>2020</year>).
<article-title>Virtual screening, molecular dynamics, density functional theory and
quantitative structure activity relationship studies to design peroxisome
proliferator-activated receptor-&#x003b3; agonists as anti-diabetic drugs</article-title>.
<source><italic toggle="yes">Journal of Biomolecular Structure and
Dynamics</italic></source>, <fpage>1</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1714482</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Khan</surname><given-names>F.</given-names></name></person-group>
(<year>2017</year>). <article-title>3D-QSAR studies on maslinic acid analogs for
anticancer activity against breast cancer cell line</article-title>. <source><italic toggle="yes">Scientific Reports</italic></source>, (<issue>1</issue>), <fpage>13</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-06131-0</pub-id><pub-id pub-id-type="pmid">28144038</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>N.
A.</given-names></name>, <name name-style="western"><surname>Sept</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Joseph</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Holst</surname><given-names>M. J.</given-names></name>, &#x00026;
<name name-style="western"><surname>McCammon</surname><given-names>J.
A.</given-names></name></person-group> (<year>2001</year>).
<article-title>Electrostatics of nanosystems: Application to microtubules and the
ribosome</article-title>. <source><italic toggle="yes">Proceedings of the National
Academy of Sciences of the United States of America</italic></source>, (<issue>18</issue>),
<fpage>10037</fpage>&#x02013;<lpage>10041</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.181342398</pub-id><pub-id pub-id-type="pmid">11517324</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedford</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Enria</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Giesecke</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Heymann</surname><given-names>D. L.</given-names></name>,
<name name-style="western"><surname>Ihekweazu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kobinger</surname><given-names>G.</given-names></name>,
<name name-style="western"><surname>Lane</surname><given-names>H.
C.</given-names></name>, <name name-style="western"><surname>Memish</surname><given-names>Z.</given-names></name>,
<name name-style="western"><surname>Oh</surname><given-names>M.-D.</given-names></name>, <name name-style="western"><surname>Sall</surname><given-names>A. A.</given-names></name>,
<name name-style="western"><surname>Schuchat</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ungchusak</surname><given-names>K.</given-names></name>, &#x00026;
<name name-style="western"><surname>Wieler</surname><given-names>L.
H.</given-names></name></person-group> (<year>2020</year>).
<article-title>COVID-19: Towards controlling of a pandemic</article-title>.
<source><italic toggle="yes">The Lancet</italic></source>, (<issue>10229</issue>),
<fpage>1015</fpage>&#x02013;<lpage>1018</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30673-5</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.
F.-W.</given-names></name>, <name name-style="western"><surname>Kok</surname><given-names>K.-H.</given-names></name>,
<name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>To</surname><given-names>K.
K.-W.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name>, &#x00026;
<name name-style="western"><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group> (<year>2020</year>).
<article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus
isolated from a patient with atypical pneumonia after visiting Wuhan</article-title>.
<source><italic toggle="yes">Emerging Microbes &#x00026; Infections</italic></source>,
(<issue>1</issue>),
<fpage>221</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id><pub-id pub-id-type="pmid">31987001</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name></person-group>
(<year>2006</year>). <article-title>Only one protomer is active in the dimer of SARS
3C-like proteinase</article-title>. <source><italic toggle="yes">The Journal of
Biological Chemistry</italic></source>, (<issue>20</issue>), <fpage>13894</fpage>&#x02013;<lpage>13898</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M510745200</pub-id><pub-id pub-id-type="pmid">16565086</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name>, &#x00026;
<name name-style="western"><surname>Guo</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>).
<article-title>Emerging coronaviruses: Genome structure, replication, and
pathogenesis</article-title>. <source><italic toggle="yes">Journal of Medical
Virology</italic></source>, (<issue>4</issue>), <fpage>418</fpage>&#x02013;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id><pub-id pub-id-type="pmid">31967327</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Chirag</surname><given-names>N.
P.</given-names></name>, <name name-style="western"><surname>Prasanth
Kumar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Himanshu</surname><given-names>A.
P.</given-names></name>, &#x00026; <name name-style="western"><surname>Rakesh</surname><given-names>M.
R.</given-names></name></person-group> (<year>2020</year>). Identification of
potential binders of the SARS-Cov-2 spike protein via molecular docking, dynamics
simulation and binding free energy calculation. <italic>chemRxiv</italic>
<pub-id pub-id-type="doi">10.26434/chemrxiv.12278588.v1</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Contini</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>).
Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins.
<ext-link ext-link-type="uri" xlink:href="https://chemrxiv.org/articles/Virtual_Screening_of_an_FDA_Approved_Drugs_Database_on_Two_COVID-19_Coronavirus_Proteins/11847381/files/21713028.pdf">https://chemrxiv.org/articles/Virtual_Screening_of_an_FDA_Approved_Drugs_Database_on_Two_COVID-19_Coronavirus_Proteins/11847381/files/21713028.pdf</ext-link></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dallakyan</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Olson</surname><given-names>A.
J.</given-names></name></person-group> (<year>2015</year>).
<article-title>Small-molecule library screening by docking with PyRx</article-title>.
<source><italic toggle="yes">Methods in Molecular Biology (Clifton,
N.J.)</italic></source>, ,
<fpage>243</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2269-7_19</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Sousa</surname><given-names>A. C.
C.</given-names></name>, <name name-style="western"><surname>Combrinck</surname><given-names>J. M.</given-names></name>,
<name name-style="western"><surname>Maepa</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Egan</surname><given-names>T.
J.</given-names></name></person-group> (<year>2020</year>).
<article-title>Virtual screening as a tool to discover new &#x003b2;-haematin inhibitors with
activity against malaria parasites</article-title>. <source><italic toggle="yes">Scientific Reports</italic></source>, (<issue>1</issue>), <fpage>3374</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-020-60221-0</pub-id><pub-id pub-id-type="pmid">32099045</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickson</surname><given-names>C.
J.</given-names></name>, <name name-style="western"><surname>Madej</surname><given-names>B. D.</given-names></name>,
<name name-style="western"><surname>Skjevik</surname><given-names>&#x000c5;.
A.</given-names></name>, <name name-style="western"><surname>Betz</surname><given-names>R. M.</given-names></name>,
<name name-style="western"><surname>Teigen</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Gould</surname><given-names>I. R.</given-names></name>, &#x00026;
<name name-style="western"><surname>Walker</surname><given-names>R.
C.</given-names></name></person-group> (<year>2014</year>).
<article-title>Lipid14: The amber lipid force field</article-title>. <source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source>,
(<issue>2</issue>),
<fpage>865</fpage>&#x02013;<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1021/ct4010307</pub-id><pub-id pub-id-type="pmid">24803855</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A.
A.</given-names></name></person-group> (<year>2020</year>).
<article-title>Anti-HCV, nucleotide inhibitors, repurposing against
COVID-19</article-title>. <source><italic toggle="yes">Life Sciences</italic></source>,
, <fpage>117477</fpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2020.117477</pub-id><pub-id pub-id-type="pmid">32119961</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fakayode</surname><given-names>S.
O.</given-names></name>, <name name-style="western"><surname>Busch</surname><given-names>K. W.</given-names></name>, &#x00026;
<name name-style="western"><surname>Busch</surname><given-names>M.
A.</given-names></name></person-group> (<year>2009</year>).
<article-title>Chemometric approach to chiral recognition using molecular
spectroscopy</article-title>. <source><italic toggle="yes">Encyclopedia of Analytical
Chemistry</italic></source>. <pub-id pub-id-type="doi">10.1002/9780470027318.a9082</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fakayode</surname><given-names>S.
O.</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>B. S.</given-names></name>, &#x00026;
<name name-style="western"><surname>Pollard</surname><given-names>D.
A.</given-names></name></person-group> (<year>2014</year>).
<article-title>Determination of boiling point of petrochemicals by gas
chromatography-mass spectrometry and multivariate regression analysis of structural
activity relationship</article-title>. <source><italic toggle="yes">Talanta</italic></source>, ,
<fpage>151</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1016/j.talanta.2014.03.037</pub-id></mixed-citation></ref><ref id="CIT0600"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A.,
Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., &#x00026; Petersson, G. A.
(2009). Gaussian 09, A.02. Gaussian, Inc.</collab></person-group></element-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funar-Timofei</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Borota</surname><given-names>A.</given-names></name>, &#x00026;
<name name-style="western"><surname>Crisan</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>).
<article-title>Combined molecular docking and QSAR study of fused heterocyclic herbicide
inhibitors of D1 protein in photosystem II of plants</article-title>. <source><italic toggle="yes">Molecular Diversity</italic></source>, (<issue>2</issue>), <fpage>437</fpage>&#x02013;<lpage>454</lpage>.
<pub-id pub-id-type="doi">10.1007/s11030-017-9735-x</pub-id><pub-id pub-id-type="pmid">28299584</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorbalenya</surname><given-names>A.
E.</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>S. C.</given-names></name>,
<name name-style="western"><surname>Baric</surname><given-names>R.
S.</given-names></name>, <name name-style="western"><surname>de
Groot</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Gulyaeva</surname><given-names>A. A.</given-names></name>,
<name name-style="western"><surname>Haagmans</surname><given-names>B.
L.</given-names></name>, <name name-style="western"><surname>Lauber</surname><given-names>C.</given-names></name>,
<name name-style="western"><surname>Leontovich</surname><given-names>A.
M.</given-names></name>, <name name-style="western"><surname>Neuman</surname><given-names>B. W.</given-names></name>,
<name name-style="western"><surname>Penzar</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name>,
<name name-style="western"><surname>Poon</surname><given-names>L. L.
M.</given-names></name>, <name name-style="western"><surname>Samborskiy</surname><given-names>D. V.</given-names></name>,
<name name-style="western"><surname>Sidorov</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name>, &#x00026;
<name name-style="western"><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>).
<article-title>The species Severe acute respiratory syndrome-related coronavirus:
Classifying 2019-nCoV and naming it SARS-CoV-2</article-title>. <source><italic toggle="yes">Nature Microbiology</italic></source>, (<issue>4</issue>), <fpage>536</fpage>&#x02013;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilgenfeld</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Peiris</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>).
<article-title>From SARS to MERS: 10 years of research on highly pathogenic human
coronaviruses</article-title>. <source><italic toggle="yes">Antiviral
Research</italic></source>, (<issue>1</issue>), <fpage>286</fpage>&#x02013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.08.015</pub-id><pub-id pub-id-type="pmid">24012996</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, &#x02026; <name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name></person-group>
(<year>2020</year>). <article-title>Clinical features of patients infected with 2019
novel coronavirus in Wuhan</article-title>. <source><italic toggle="yes">The <italic toggle="yes">Lancet</italic></italic></source>, (<issue>10223</issue>), <fpage>497</fpage>&#x02013;<lpage>506</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">32164906</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>J.
J.</given-names></name>, &#x00026; <name name-style="western"><surname>Shoichet</surname><given-names>B.
K.</given-names></name></person-group> (<year>2005</year>). <article-title>ZINC-a
free database of commercially available compounds for virtual screening</article-title>.
<source><italic toggle="yes">Journal of Chemical Information and
Modeling</italic></source>, (<issue>1</issue>), <fpage>177</fpage>&#x02013;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1021/ci049714+</pub-id><pub-id pub-id-type="pmid">15667143</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>M.
J.</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>A. M.</given-names></name>,
<name name-style="western"><surname>Parves</surname><given-names>M.
R.</given-names></name>, <name name-style="western"><surname>Hossain</surname><given-names>M. N.</given-names></name>, &#x00026;
<name name-style="western"><surname>Halim</surname><given-names>M.
A.</given-names></name></person-group> (<year>2019</year>).
<article-title>Prediction of deleterious non-synonymous SNPs of human STK11 gene by
combining algorithms, molecular docking, and molecular dynamics
simulation</article-title>. <source><italic toggle="yes">Scientific
Reports</italic></source>, (<issue>1</issue>), <fpage>16426</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-019-52308-0</pub-id><pub-id pub-id-type="pmid">31712642</pub-id></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Parves</surname><given-names>M. R.</given-names></name>,
<name name-style="western"><surname>Paul</surname><given-names>A.
S.</given-names></name>, <name name-style="western"><surname>Uddin</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>M.
S.</given-names></name>, <name name-style="western"><surname>Mamun</surname><given-names>A. A.</given-names></name>, Hossain,
Md. <name name-style="western"><surname>Md.
Ali</surname><given-names>N.A.</given-names></name>, &#x00026; <name name-style="western"><surname>Halim</surname><given-names>M.
A.</given-names></name></person-group> (<year>2020</year>). <article-title>A
molecular modeling approach to identify effective antiviral phytochemicals against the
main protease of SARS-CoV-2</article-title>. <source><italic toggle="yes">Journal of
Biomolecular Structure and Dynamics</italic></source>,
<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761883</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>You</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, &#x02026; <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group>
(<year>2020</year>). <article-title>Structure of M<sup>pro</sup> from COVID-19 virus and
discovery of its inhibitors</article-title>. <source><italic toggle="yes">BioRxiv</italic></source>, <volume>2020</volume>02.26.964882. <pub-id pub-id-type="doi">10.1101/2020.02.26.964882</pub-id></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Willett</surname><given-names>P.</given-names></name>,
<name name-style="western"><surname>Glen</surname><given-names>R.
C.</given-names></name>, <name name-style="western"><surname>Leach</surname><given-names>A. R.</given-names></name>, &#x00026;
<name name-style="western"><surname>Taylor</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>).
<article-title>Development and validation of a genetic algorithm for flexible docking 1
1Edited by F. E. Cohen</article-title>. <source><italic toggle="yes">Journal of
Molecular Biology</italic></source>, (<issue>3</issue>), <fpage>727</fpage>&#x02013;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1996.0897</pub-id><pub-id pub-id-type="pmid">9126849</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassambara</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>).
<article-title>Practical guide to principal component methods in R.
</article-title><source><italic toggle="yes">STHDA</italic></source>, , 1&#x02013;170. CreateSpace Independent Publishing
Platform.</mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="report"><person-group person-group-type="author"><name name-style="western"><surname>Krieger</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Elmar</surname><given-names>G. V.</given-names></name>, &#x00026;
<name name-style="western"><surname>Spronk</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>).
YASARA&#x02013;Yet another scientific artificial reality application. <italic>YASARA.Org</italic>.</mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieger</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>J. E.</given-names></name>,
<name name-style="western"><surname>Spronk</surname><given-names>C. A. E.
M.</given-names></name>, &#x00026; <name name-style="western"><surname>Vriend</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>).
<article-title>Fast empirical pKa prediction by Ewald
summation</article-title><source><italic toggle="yes">. <italic toggle="yes">Journal
of Molecular Graphics and Modelling</italic></italic></source>, (<issue>4</issue>),
<fpage>481</fpage>&#x02013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2006.02.009</pub-id><pub-id pub-id-type="pmid">16644253</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieger</surname><given-names>E.</given-names></name>, &#x00026; <name name-style="western"><surname>Vriend</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>).
<article-title>New ways to boost molecular dynamics simulations</article-title>.
<source><italic toggle="yes">Journal of Computational Chemistry</italic></source>,
(<issue>13</issue>),
<fpage>996</fpage>&#x02013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.23899</pub-id><pub-id pub-id-type="pmid">25824339</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>, &#x02026; <name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group>
(<year>2020</year>). <article-title>Genomic characterisation and epidemiology of 2019
novel coronavirus: Implications for virus origins and receptor binding</article-title>.
<source><italic toggle="yes">The Lancet</italic></source>, (<issue>10224</issue>),
<fpage>565</fpage>&#x02013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mark</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Workman</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>).
<chapter-title>Chemometrics in spectroscopy</chapter-title> In <source><italic toggle="yes">Chemometrics in spectroscopy</italic></source>. Elsevier. <pub-id pub-id-type="doi">10.1016/B978-0-12-374024-3.X5000-4</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martens</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Naes</surname><given-names>T.</given-names></name></person-group>
(<year>1998</year>). <chapter-title>Multivariate calibration</chapter-title> In
<source><italic toggle="yes">Data handling in science and technology</italic></source>
(Vol. <volume>20</volume>). Wiley. <pub-id pub-id-type="doi">10.1016/S0922-3487(98)80046-4</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Massova</surname><given-names>I.</given-names></name>, &#x00026; <name name-style="western"><surname>Kollman</surname><given-names>P.
A.</given-names></name></person-group> (<year>2000</year>).
<article-title>Combined molecular mechanical and continuum solvent approach (MM-
PBSA/GBSA) to predict ligand binding</article-title>. <source><italic toggle="yes">Perspectives in Drug Discovery and Design</italic></source>, (<issue>1</issue>),
<fpage>113</fpage>&#x02013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1023/A:1008763014207</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paasche</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zipper</surname><given-names>A.</given-names></name>,
<name name-style="western"><surname>Sch&#x000e4;fer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ziebuhr</surname><given-names>J.</given-names></name>,
<name name-style="western"><surname>Schirmeister</surname><given-names>T.</given-names></name>, &#x00026; <name name-style="western"><surname>Engels</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>).
<article-title>Evidence for substrate binding-induced zwitterion formation in the
catalytic Cys-His dyad of the SARS-CoV main protease</article-title>. <source><italic toggle="yes">Biochemistry</italic></source>, (<issue>37</issue>), <fpage>5930</fpage>&#x02013;<lpage>5946</lpage>.
<pub-id pub-id-type="doi">10.1021/bi400604t</pub-id><pub-id pub-id-type="pmid">25196915</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos-Filho</surname><given-names>O.
A.</given-names></name>, <name name-style="western"><surname>Hopfinger</surname><given-names>A. J.</given-names></name>,
<name name-style="western"><surname>Cherkasov</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>de Alencastro</surname><given-names>R.
B.</given-names></name></person-group> (<year>2009</year>). <article-title>The
receptor-dependent QSAR paradigm: An overview of the current state of the
art</article-title>. <source><italic toggle="yes">Medicinal Chemistry (Shariqah (United
Arab Emirates))</italic></source>, (<issue>4</issue>), <fpage>359</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.2174/157340609788681458</pub-id><pub-id pub-id-type="pmid">19689393</pub-id></mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Sekhar</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>).
<italic>Virtual screening based prediction of potential drugs for
COVID-19</italic>
<pub-id pub-id-type="doi">10.20944/preprints202002.0418.v2</pub-id></mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sexton</surname><given-names>N.
R.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>E. C.</given-names></name>,
<name name-style="western"><surname>Blanc</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Vignuzzi</surname><given-names>M.</given-names></name>,
<name name-style="western"><surname>Peersen</surname><given-names>O.
B.</given-names></name>, &#x00026; <name name-style="western"><surname>Denison</surname><given-names>M.
R.</given-names></name></person-group> (<year>2016</year>).
<article-title>Homology-based identification of a mutation in the coronavirus
RNA-dependent RNA polymerase that confers resistance to multiple
mutagens</article-title>. <source><italic toggle="yes">Journal of
Virology</italic></source>, (<issue>16</issue>), <fpage>7415</fpage>&#x02013;<lpage>7428</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.00080-16</pub-id><pub-id pub-id-type="pmid">27279608</pub-id></mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaghaghi</surname><given-names>N.</given-names></name></person-group> (<year>2020</year>).
<article-title>Molecular docking study of novel COVID-19 protease with low risk
terpenoides compounds of plants</article-title>. <source><italic toggle="yes">ChemRxiv</italic></source>, (<issue>1</issue>). <pub-id pub-id-type="doi">10.26434/chemrxiv.11935722.v1</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Almaz&#x000e1;n</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Z&#x000fa;&#x000f1;iga</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>).
<article-title>Continuous and discontinuous RNA synthesis in
coronaviruses</article-title>. <source><italic toggle="yes">Annual Review of
Virology</italic></source>, (<issue>1</issue>), <fpage>265</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-virology-100114-055218</pub-id></mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Studio</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>).
<source><italic toggle="yes">Dassault systemes BIOVIA, Discovery studio modelling
environment, Release 4.5</italic></source>. <publisher-name>Accelrys Software
Inc</publisher-name>.</mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ton</surname><given-names>A.-T.</given-names></name>, <name name-style="western"><surname>Gentile</surname><given-names>F.</given-names></name>,
<name name-style="western"><surname>Hsing</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ban</surname><given-names>F.</given-names></name>, &#x00026;
<name name-style="western"><surname>Cherkasov</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>).
<article-title>Rapid identification of potential inhibitors of SARS-CoV-2 main protease
by deep docking of 1.3 billion compounds</article-title>. <source><italic toggle="yes">Molecular Informatics</italic></source>
<pub-id pub-id-type="doi">10.1002/minf.202000028</pub-id></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Khedkar</surname><given-names>V.</given-names></name>, &#x00026;
<name name-style="western"><surname>Coutinho</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>).
<article-title>3D-QSAR in drug design-a review</article-title>. <source><italic toggle="yes">Current Topics in Medicinal Chemistry</italic></source>, (),
<fpage>95</fpage>&#x02013;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.2174/156802610790232260</pub-id><pub-id pub-id-type="pmid">19929826</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Worldometer.</collab></person-group> (<year>2020</year>). Coronavirus cases.
<person-group person-group-type="editor"><collab>Worldometer</collab></person-group>
<ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/coronavirus-cases/#daily-cases">https://www.worldometers.info/coronavirus/coronavirus-cases/#daily-cases</ext-link></mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Curth</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sauerhering</surname><given-names>L.</given-names></name>,
<name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Rox</surname><given-names>K.</given-names></name>, &#x00026;
<name name-style="western"><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>).
<article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design
of improved &#x003b1;-ketoamide inhibitors</article-title>. <source><italic toggle="yes">Science</italic>,</source>
<volume>3405</volume>(<volume>March</volume>), <fpage>eabb3405</fpage>
<pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id></mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>W.</given-names></name>, &#x00026; <name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>).
<article-title>Network-based drug repurposing for novel coronavirus
2019-nCoV/SARS-CoV-2</article-title>. <source><italic toggle="yes">Cell
Discovery</italic></source>, (<issue>1</issue>) <fpage>14</fpage>
<pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id><pub-id pub-id-type="pmid">32194980</pub-id></mixed-citation></ref></ref-list></back></article>